gp100和酪氨酸酶多肽接种在治疗黑色素瘤患者黑痣中的疗效  

The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients

作　　者：Cassarino D.S. Miller W.J. Auerbach A. 吴佳纹 

机构地区：[1]Department of Pathology, Stanford University, School of Medicine, 300 Pasteur Drive, Lane 235, Stanford, CA 94305- 5324, United States Dr.

出　　处：《世界核心医学期刊文摘（皮肤病学分册）》2006年第8期56-57,共2页Digest of the World Core Medical JOurnals:Dermatology

摘　　要：Background: A new approach to prevent disease recurrence in high-risk melanoma patients involves immunization with gp100 and tyrosinase peptides. This is the first study to examine the effects of such treatments on nevi. Design: We studied biopsies of ‘ clinically atypical’ nevi from 10 patients before and after peptide vaccination. All had a cutaneous melanoma measuring at least 1.5 mm in depth, satellite metastases, or at least one positive lymph node. We performed immunohistochemical stains for CD3, CD4, CD8, MHC-I, MHC-II, CD1a, HMB-45, MART-1, tyrosinase, bcl-2, p53, and Ki-67 (mib-1). Results: Immunohistochemistry showed no differences in staining due to vaccination in either the immunologic or melanocytic markers. However, there was a significant increase in both p53 and bcl-2 staining, and a trend toward decreased Ki-67 staining, in the nevi post-treatment. Discussion: The primary goal of peptide vaccinations with gp100 and tyrosinase is to activate melanoma-specific T cells in order to prevent melanoma recurrence. Nevi were studied in order to assess the effects on benign melanocytes. No significant changes in lymphocytes, langerhans cells, expression of MHC antigens, or melanocytic markers were found. The increase in p53 and bcl-2 raises the possibility that vaccination with melanocytic antigens stimulates a response in benign melanocytes.Background： A new approach to prevent disease recurrence in high-risk melanoma patients involves immunization with gp100 and tyrosinase peptides. This is the first study to examine the effects of such treatments on nevi. Design： We studied biopsies of ＇clinically atypical＇ nevi from 10 patients before and after peptide vaccination. All had a cutaneous melanoma measuring at least 1.5 mm in depth, satellite metastases, or at least one positive lymph node. We performed immunohistochemical stains for CD3, CD4, CD8, MHC-I, MHC-II, CDla, HMB-45, MART-1, tyrosinase, bcl-2, p53, and Ki-67 （mib-1） . Results： Immunohistochemistry showed no differences in staining due to vaccination in either the immunologic or melanocytic markers. However, there was a significant increase in both p53 and bcl-2 staining, and a trend toward decreased Ki-67 staining, in the nevi post-treatment. Discussion： The primary goal of peptide vaccinations with gplO0 and tyrosinase is to activate melanoma-specific T cells in order to prevent melanoma recurrence. Nevi were studied in order to assess the effects on benign melanocytes. No significant changes in lymphocytes, langerhans cells, expression of MHC antigens,

关 键 词：皮肤黑色素瘤 免疫接种 gp100 酪氨酸酶 治疗方法 治疗效应 黑痣 患者 多肽 免疫组化染色 

分 类 号：R739.5[医药卫生—肿瘤] R186[医药卫生—临床医学]